apixaban

GPTKB entity

Statements (43)
Predicate Object
gptkbp:instance_of gptkb:fragrance
gptkbp:activities factor Xa inhibitor
gptkbp:appointed_by oral tablet
gptkbp:approves gptkb:2012
gptkb:FDA
gptkbp:brand gptkb:Eliquis
gptkbp:clinical_trial Phase III
gptkbp:contraindication active bleeding
severe renal impairment
strong CY P3 A4 inducers
strong CY P3 A4 inhibitors
hypersensitivity to apixaban
gptkbp:developed_by gptkb:Bristol-Myers_Squibb
gptkbp:dosage_form 5 mg tablet
2.5 mg tablet
gptkbp:excretion kidneys
https://www.w3.org/2000/01/rdf-schema#label apixaban
gptkbp:interacts_with gptkb:HIV_protease_inhibitors
certain antibiotics
antiplatelet agents
other anticoagulants
certain antifungals
gptkbp:is_available_in many countries
gptkbp:is_available_on generic version
gptkbp:is_monitored_by renal function
liver function
gptkbp:is_used_for preventing blood clots
reducing the risk of stroke
treating deep vein thrombosis
treating pulmonary embolism
gptkbp:lifespan 8 to 15 hours
gptkbp:marketed_as anticoagulant therapy
gptkbp:metabolism liver
gptkbp:side_effect nausea
bruising
bleeding
gptkbp:suitable_for pregnancy
breastfeeding
gptkbp:used_in gptkb:atrial_fibrillation
venous thromboembolism
gptkbp:bfsParent gptkb:deep_vein_thrombosis
gptkb:Eliquis
gptkbp:bfsLayer 4